Phreesia, Inc. (PHR)
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
$12.44-0.72%
Close 2026-10-30 · 1-day change
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
Research Workspace
Put PHR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 13% over the past year and decelerating.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 1% on a typical day and fell roughly 65% in its worst 12-month stretch.
View RiskPhreesia’s case rests on strong recent performance, but revenue growth is slowing and visibility is fading. The FY2027 revenue objective is $510M-$520M. Latest Q2 FY2027 revenue grew 10% year over year, while reported GAAP EPS missed consensus. PHR trades at 13× P/E versus a 25× peer median. The price reflects less growth than our forecast, despite the latest earnings miss. Our model puts the next-quarter miss probability near 50%. Peer multiples imply a price about 19% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. PHR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering PHR (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for PHR in the last 4 months.
Continue this research
Compare PHR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PHR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put PHR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Revenue growth to $510M-$520M for FY 2027
Growth visibility fading could impact revenue targets.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $12.44
The last 12 months of price, then the range of analyst 12-month targets from today’s $12.44.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Revenue growth to $510M-$520M for FY 2027
Profit turnaround may not sustain revenue growth targets.
Threatens: Revenue growth to $510M-$520M for FY 2027
Downgrade indicates concerns over revenue growth trajectory.
Advances: Adjusted EBITDA target of $125M-$135M for FY 2027
Record EBITDA margin supports adjusted EBITDA target for FY 2027.
Advances: Revenue growth to $510M-$520M for FY 2027
Maintaining revenue outlook supports growth objectives.
Potential legal issues could impact investor confidence and operations.
Class action may distract from management's focus on growth.
Advances: Adjusted EBITDA target of $125M-$135M for FY 2027
Strong earnings quality supports revenue growth objective.